The impact of reduced dosing frequency of elranatamab on patient‐reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM‐3

Схожие документы

• P35 | PROLONGED ELRANATAMAB TREATMENT INTERRUPTION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MagnetisMM-3 RETROSPECTIVE ANALYSIS
  по: E. Searle, и др.
  Опубликовано: (2026-04-01)
• The impact of reduced dosing frequency of elranatamab on patient‐reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM‐3
  по: Nizar J. Bahlis, и др.
  Опубликовано: (2025-09-01)
• ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY
  по: M Mohty, и др.
  Опубликовано: (2023-10-01)
• EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
  по: N Raje, и др.
  Опубликовано: (2023-10-01)
• P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3
  по: A. M. Lesokhin, и др.
  Опубликовано: (2022-06-01)